Patents by Inventor Brian G. Pierce

Brian G. Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODIFIED SECRETED HEPATITIS C VIRUS (HCV) E1E2 GLYCOPROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240016923
    Abstract: Disclosed are modified hepatitis C virus (HCV) E1E2 glycoproteins. Disclosed are Disclosed are modified HCV E1E2 glycoproteins comprising a HCV E1 polypeptide; a first scaffold element; a HCV E2 polypeptide; and a second scaffold element, wherein the HCV E1 polypeptide does not comprise a transmembrane domain, and wherein the HCV E2 polypeptide does not comprise a transmembrane domain.
    Type: Application
    Filed: November 12, 2021
    Publication date: January 18, 2024
    Inventors: Brian G. Pierce, Thomas R. Fuerst, Eric A. Toth, Johnathan D. Guest, Steven K.H. Foung, Zhen-Yong Keck
  • MODIFIED HEPATITIS C VIRUS E2 GLYCOPROTEINS AND METHODS OF USE THEREOF
    Publication number: 20220054630
    Abstract: Disclosed are modified HCV E2 glycoproteins. Disclosed are modified HCV E2 glycoproteins comprising an antigenic domain D, wherein the modified HCV E2 glycoproteins comprise one or more amino acid alterations in the antigenic domain D, wherein at least one amino acid alteration is a proline substitution. In some aspects, the proline substitution occurs at position 445 based on the amino acid numbering of HCV strain H77. Disclosed are modified HCV E2 glycoproteins comprising an antigenic domain A, wherein the antigenic domain A comprises an N-glycan sequon substitution. In some aspects, the N-glycan sequon substitution results in an Asn-Xaa-Ser or Asn-Xaa-Thr substitution, wherein Xaa is any amino acid except proline. Also disclosed are methods of using the disclosed modified HCV E2 glycoproteins, such as methods of inducing an immune response in a subject, methods of treating a subject, and methods of increasing antigenicity of HCV E2 glycoprotein.
    Type: Application
    Filed: August 18, 2021
    Publication date: February 24, 2022
    Inventors: Brian G. Pierce, Thomas R. Fuerst, Roy A. Mariuzza, Steven K.H. Foung, Zhen-Yong Keck
  • High-affinity DMF5 T cell receptor (TCR) variants
    Patent number: 9717758
    Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 1, 2017
    Assignees: University of Massachusetts, University of Notre Dame du Lac
    Inventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker
  • High-Affinity DMF5 T Cell Receptor (TCR) Variants
    Publication number: 20140341809
    Abstract: High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient.
    Type: Application
    Filed: May 16, 2014
    Publication date: November 20, 2014
    Applicants: University of Massachusetts, University of Notre Dame
    Inventors: Brian G. Pierce, Zhiping Weng, Brian M. Baker